A5091828453- Cholangiocarcinoma and Gallbladder Cancer Studies
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Drug Transport and Resistance Mechanisms
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Protein Degradation and Inhibitors
- Liver physiology and pathology
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Cancer Mechanisms and Therapy
- MicroRNA in disease regulation
- Ubiquitin and proteasome pathways
Paracelsus Medical University
2020-2025
Biliary tract cancer (BTC) is a gastrointestinal malignancy associated with poor survival rate. Current therapies encompass palliative and chemotherapeutic treatment as well radiation therapy, which results in median of only one year due to standard therapeutic ineffectiveness or resistance. Tazemetostat an FDA-approved inhibitor enhancer Zeste homolog 2 (EZH2), methyltransferase involved BTC tumorigenesis via trimethylation histone 3 at lysine 27 (H3K27me3), epigenetic mark silencing tumor...
Inhibition of histone deacetylases (HDACs) is a promising anti-cancer approach. For biliary tract cancer (BTC), only limited therapeutic options are currently available. Therefore, we performed comprehensive investigation HDAC expression and pharmacological inhibition into panel eight established BTC cell lines. The screening results indicate heterogeneous HDACs across the studied We next tested effect six inhibitors (HDACi) covering pan- class-specific HDACis on viability cells found that...
Introduction Biliary tract cancer (BTC) is a lethal disease with bad overall survivability, partly arising from inadequate therapeutic alternatives, detection at belated stage, and resistance to common approaches. Ferroptosis form of programmed cell death that depends on reactive oxygen species (ROS) iron, causing excessive peroxidation polyunsaturated fatty acids (PUFAs). Therefore, the objective this investigation is, whether ferroptosis can be induced in BTC vitro induction dependent...
Biliary tract cancer is a deadly disease with limited therapeutic options. Ouabain well-known inhibitor of the pumping function Na+/K+-ATPase, though there evidence that low concentrations ouabain lead to reduction cell viability cells independent its inhibition Na+/K+-ATPase. Regarding impact on biliary cancer, no data currently available. Therefore, we aimed for first-time investigation as potential anti-neoplastic agent using comprehensive human in vitro models. We found has strong...
Introduction Biliary tract cancer (BTC) is a fatal disease with limited therapeutic options. Inhibition of histone deacetylases (HDACs) represents an effective anti-cancer approach. Data regarding HDAC and BTC are sparse but promising. There, we performed comprehensive investigation expression pharmacological inhibition in vitro model. Methods Expression HDACs cells was measured via quantitative real-time PCR immunohistochemistry. Cytotoxicity pan-inhibitors (belinostat, vorinostat)...
• This editorial provides a brief overview of the role HDACs in diffuse large B-cell lymphoma (DLBCL). Possible mechanisms HDAC inhibitor resistance DLBCL are discussed detail. It highlights need for developing isoform-specific inhibitors. Additional combinatory regimens and dual-specificity inhibitors may increase therapeutic efficacy inhibition this aggressive lymphoma.
Introduction:Although molecular insights about biliary tract cancer (BTC) increased in the last decade, new therapeutic strategy like inhibition of histone deacetylases (HDACs) could additionally improve still dismal outcome this tumor entity.Methods: Therefore, we performed comprehensive investigation HDAC expression and pharmacological a panel eight established BTC cell lines cohort resected native specimens (n = 78).Results: profiling revealed heterogeneous HDACs across studied...